FDA Clears Emerging 3D Ultrasound Technology
The diagnostic tomographic 3D ultrasound imaging technology PIUR tUS inside will reportedly be available with select GE HealthCare Logiq systems.
Emphasizing proprietary sensor technology to provide tomographic 3D ultrasound imaging, the PIUR tUS inside modality has garnered 510(k) clearance from the Food and Drug Administration (FDA).
The PIUR tUS inside , which will be available with select GE HealthCare Logiq ultrasound systems, offers a combination of enhanced imaging, automated reporting and artificial intelligence (AI)-enabled segmentation, according to PIUR Imaging, the developer of PIUR tUS inside.
Key attributes of the recently FDA-cleared PIUR tUS inside ultrasound modality include automated volume and nodule assessments, 3D image reconstruction and automated thyroid reporting. The PIUR tUS inside modality will be available with select GE HealthCare Logiq ultrasound systems, according to PIUR Imaging, the developer of PIUR tUS inside. (Image courtesy of PIUR Imaging.)
The company noted that key attributes of PIUR tUS inside include:
• automated 3D reconstruction of sagittal, transverse and coronal views from one sweep;
• automated volume and nodule assessment;
• AI-powered 3D segmentation with nodule and lobe measurements; and
• a combination of automated thyroid reporting and PACS integration for streamlined documentation.
“With the combination of this integrated solution and our previously FDA cleared Infinity system, PIUR IMAGING will continue to strengthen the role of enhanced 3D ultrasound imaging to improve patient outcomes in the U.S.,” said Tullio Giannitti, the general manager of PIUR Imaging.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
